132 related articles for article (PubMed ID: 17187314)
1. The development of chalcones as promising anticancer agents.
Ducki S
IDrugs; 2007 Jan; 10(1):42-6. PubMed ID: 17187314
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of a series of tangeretin-derived chalcones.
Quintin J; Desrivot J; Thoret S; Le Menez P; Cresteil T; Lewin G
Bioorg Med Chem Lett; 2009 Jan; 19(1):167-9. PubMed ID: 19013795
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of thiophene analogues of chalcones.
Romagnoli R; Baraldi PG; Carrion MD; Cara CL; Cruz-Lopez O; Preti D; Tolomeo M; Grimaudo S; Di Cristina A; Zonta N; Balzarini J; Brancale A; Sarkar T; Hamel E
Bioorg Med Chem; 2008 May; 16(10):5367-76. PubMed ID: 18440234
[TBL] [Abstract][Full Text] [Related]
4. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
5. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
6. Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells.
Loa J; Chow P; Zhang K
Cancer Chemother Pharmacol; 2009 May; 63(6):1007-16. PubMed ID: 18766342
[TBL] [Abstract][Full Text] [Related]
7. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
[TBL] [Abstract][Full Text] [Related]
8. Effects of alpha-substitutions on structure and biological activity of anticancer chalcones.
Lawrence NJ; Patterson RP; Ooi LL; Cook D; Ducki S
Bioorg Med Chem Lett; 2006 Nov; 16(22):5844-8. PubMed ID: 16949281
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol).
Miyazawa T; Shibata A; Sookwong P; Kawakami Y; Eitsuka T; Asai A; Oikawa S; Nakagawa K
J Nutr Biochem; 2009 Feb; 20(2):79-86. PubMed ID: 19071006
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents.
Dupeyre G; Chabot GG; Thoret S; Cachet X; Seguin J; Guénard D; Tillequin F; Scherman D; Koch M; Michel S
Bioorg Med Chem; 2006 Jul; 14(13):4410-26. PubMed ID: 16529936
[TBL] [Abstract][Full Text] [Related]
12. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
Boumendjel A; Boccard J; Carrupt PA; Nicolle E; Blanc M; Geze A; Choisnard L; Wouessidjewe D; Matera EL; Dumontet C
J Med Chem; 2008 Apr; 51(7):2307-10. PubMed ID: 18293907
[TBL] [Abstract][Full Text] [Related]
13. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
14. Recent advances of cytotoxic chalconoids targeting tubulin polymerization: Synthesis and biological activity.
Mirzaei H; Emami S
Eur J Med Chem; 2016 Oct; 121():610-639. PubMed ID: 27318983
[TBL] [Abstract][Full Text] [Related]
15. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer chalcones: Structural and molecular target perspectives.
Mahapatra DK; Bharti SK; Asati V
Eur J Med Chem; 2015 Jun; 98():69-114. PubMed ID: 26005917
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in therapeutic applications of chalcones.
Katsori AM; Hadjipavlou-Litina D
Expert Opin Ther Pat; 2011 Oct; 21(10):1575-96. PubMed ID: 21711087
[TBL] [Abstract][Full Text] [Related]
18. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).
Lebedeva IV; Emdad L; Su ZZ; Gupta P; Sauane M; Sarkar D; Staudt MR; Liu SJ; Taher MM; Xiao R; Barral P; Lee SG; Wang D; Vozhilla N; Park ES; Chatman L; Boukerche H; Ramesh R; Inoue S; Chada S; Li R; De Pass AL; Mahasreshti PJ; Dmitriev IP; Curiel DT; Yacoub A; Grant S; Dent P; Senzer N; Nemunaitis JJ; Fisher PB
Int J Oncol; 2007 Nov; 31(5):985-1007. PubMed ID: 17912425
[TBL] [Abstract][Full Text] [Related]
19. Microtubule assembly dynamics: an attractive target for anticancer drugs.
Singh P; Rathinasamy K; Mohan R; Panda D
IUBMB Life; 2008 Jun; 60(6):368-75. PubMed ID: 18384115
[TBL] [Abstract][Full Text] [Related]
20. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents.
Mabeta P; Pepper MS
Angiogenesis; 2009; 12(1):81-90. PubMed ID: 19214765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
